879743-76-7

Upstream product

• 41011-01-2 2-bromo-1-(3-chloro-phenyl)-ethanone 
• 1074-82-4 potassium phtalimide 
• 587-04-2 m-Chlorobenzaldehyde 
• 13078-79-0 2-(3-chlorophenyl)ethylamine 
• 37888-03-2 3-chloroβ-nitrostyrene 

Downstream Products

• 1224944-70-0 2-(3-(3-chlorophenyl)-1-(dimethylamino)-3-oxoprop-1-en-2-yl)isoindoline-1,3-dione 
• 1224944-71-1 3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-amine 
• 1260162-48-8 N-(3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1282538-56-0 5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-amine 
• 1224942-05-5 N-(3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl)-5-(cyclopropylmethylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1224943-37-6 5-amino-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [3-(3-chloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-amide 
• 1260163-16-3 N-[3-(3-chlorophenyl)-1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1224944-72-2 5-chloro-N-(3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant academic research and scientific papers

Combined Photoredox/Enzymatic C?H Benzylic Hydroxylations

Chemical transformations that install heteroatoms into C?H bonds are of significant interest because they streamline the construction of value-added small molecules. Direct C?H oxyfunctionalization, or the one step conversion of a C?H bond to a C?O bond, could be a highly enabling transformation due to the prevalence of the resulting enantioenriched alcohols in pharmaceuticals and natural products,. Here we report a single-flask photoredox/enzymatic process for direct C?H hydroxylation that proceeds with broad reactivity, chemoselectivity and enantioselectivity. This unified strategy advances general photoredox and enzymatic catalysis synergy and enables chemoenzymatic processes for powerful and selective oxidative transformations.

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

Discovery of potent and selective pyrazolopyrimidine Janus kinase 2 inhibitors

The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the p

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient. Ia